Management strategies and clinical outcomes in breast cancer patients who develop left ventricular dysfunction during trastuzumab therapy

BACKGROUND: Trastuzumab reduces risk of breast cancer recurrence but carries risk of cardiotoxicity that may be reversible upon treatment cessation and institution of left ventricular (LV) enhancement therapies (LVETx). We assessed management patterns of trastuzumab-induced cardiotoxicity (TIC) in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Ren Jie Robert, Gibson, Jordan, Simmons, Christine, Davis, Margot K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995775/
https://www.ncbi.nlm.nih.gov/pubmed/33766148
http://dx.doi.org/10.1186/s40959-021-00099-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995775/
https://www.ncbi.nlm.nih.gov/pubmed/33766148
http://dx.doi.org/10.1186/s40959-021-00099-7

Ejemplares similares